Rising manufacturing standards, cutting-edge novel therapeutics, and growing demand for personalized medicine spurred on this evolution, with two distinct new strategic approaches emerging: larger CDMOs are moving towards vertical integration, becoming end-to-end service providers, while smaller CDMOs are leaning into niche and complex specialisms in manufacturing and development.
